Medical AI company Harrison.ai has secured U.S. Food and Drug Administration (FDA) 510(k) clearance for its innovative Acute Infarct Triage solution. This advanced technology utilizes artificial intelligence to analyze initial non-contrast CT brain scans, aiming to accelerate the identification of suspected ischemic strokes. The clearance marks a significant milestone for the company and represents a major step forward in improving diagnostic workflows and patient outcomes in stroke care.
A New Approach to Stroke Triage
Harrison.ai's solution introduces a fundamental shift in how potential stroke patients are triaged within the hospital setting. Unlike most existing AI tools that rely on CT angiography (CTA), a more advanced scan performed later, this technology functions on the very first non-contrast CT. This capability allows for the immediate prioritization of patients with suspected ischemic strokes, ensuring they receive follow-up imaging and treatment sooner.
The system is designed to detect actual ischemic tissue damage rather than just focusing on large vessel occlusions (LVO). It comprehensively analyzes infarcts across all major vascular territories, including the ACA, MCA, PCA, and cerebellar regions. This broader scope enables the identification of a wider range of strokes that might be missed by tools with a narrower focus.
Validated Performance and Clinical Impact
Dr. Jarrel Seah, Chief Medical Officer at Harrison.ai, noted that identifying acute infarct on a non-contrast CT is one of the most difficult tasks in radiology. He stated that most radiologists will welcome the assistance in bringing these critical cases to the front of the queue. This support is vital in a clinical environment where rapid intervention is directly linked to preserving brain function and improving patient recovery.
The AI's performance was rigorously validated, achieving a sensitivity of up to 89.2 percent in detecting confirmed infarcts. The technology demonstrated greater than 80 percent sensitivity and specificity across multiple operating points for both thin and thick slice scans. This high level of accuracy was established using advanced imaging as the ground truth, confirming its reliability in a clinical setting.
Direct comparisons included in the FDA submission highlighted the solution's advantages over existing technologies. It showed superior sensitivity for identifying tissue injury compared to other cleared devices that analyze non-contrast CT scans for LVOs. This positions the tool as a unique and powerful aid for emergency physicians and radiologists in the critical early stages of stroke diagnosis.
Expanding Comprehensive AI Coverage
This latest approval is Harrison.ai's ninth FDA clearance, expanding its portfolio to cover thirteen distinct radiological findings on non-contrast CT brain scans. The platform now offers the most comprehensive AI triage coverage available for this primary imaging modality. This integrated system can now flag both hemorrhagic and ischemic strokes, streamlining the diagnostic process for emergency departments.
The acute infarct solution is one of three Harrison.ai products to earn the FDA's prestigious Breakthrough Device Designation. It is now the second of those devices to receive full marketing authorization, a distinction achieved by only about 15 percent of all breakthrough-designated technologies. This highlights the significant clinical need and the innovative nature of the AI-powered tool in addressing a life-threatening condition.
With a global presence in over 40 countries and at more than 1,000 customer sites, Harrison.ai has already impacted over seven million patients. CEO Dr. Aengus Tran emphasized that the tool can reduce critical delays, stating that “when time is brain, that has real patient impact.” The company plans to launch its Acute Infarct Triage solution across the United States in the coming months.
The FDA clearance of Harrison.ai's Acute Infarct Triage solution signifies a pivotal advancement in the early detection of ischemic stroke. By applying powerful AI to the first point of imaging, the technology is poised to accelerate diagnosis, optimize patient prioritization, and ultimately enhance clinical outcomes. This innovation marks a crucial development in the global effort to mitigate the severe and often life-altering effects of stroke.